Issue link: http://osercommunicationsgroup.uberflip.com/i/808989
Chain Drugstore Daily Sunday, April 23, 2017 2 6 CREATE A UNIFIED CUSTOMER EXPERIENCE WITH WESTROCK WestRock provides pharmacies and phar- maceutical manufacturers with unique award-winning packaging solutions that are designed to improve patient adher- ence to medication, enhance pharmacy efficiencies and increase speed to market. Shellpak ® Renew and Doseapak ® , top-selling adherence solutions, protect medication integrity and offer superior child safety (F=1) while remaining easy for adults to use. An innovative capabili- ty under the new organization is mer- chandising displays, which help drive promotion at the retail setting with tem- porary promotional and permanent point- of-purchase displays. Providing an end-to-end marketing, merchandising and packaging suite of solutions, WestRock supports the retail pharmacy's challenges comprehensively. Adherence packaging solutions not only maximize pharmacist-patient interaction opportunities, but also provide increased opportunities to satisfy CMS Star ratings and boost reimburse- ment. Merchandising displays amplify the investment many retail pharmacies have made in mobile app technology, in- store promotions and point of sale prospects by creating a unified customer experience. The Patient/Consumer Journey Your patient enters the retail store to pick up a prescription from the pharmacy. Notifications of in-store promotions appear on the patient's mobile device through the retail app. The patient makes a note to pick up the allergy medication being promoted. The patient pro- ceeds to the pharmacy and has a meaning- ful educational interaction with the phar- macist, who explains the cholesterol medication regimen and side effects, and the importance of compliance to maxi- mize symptom improvement. The patient then goes to pick up Allergy Med X from the WestRock display. The patient also pulls an in-store coupon off the display for $2 off tissues, finishes shopping and proceeds to checkout. For more information, visit booth #690. ASCEND LABORATORIES KEEPS CLEAR FOCUS Ascend Laboratories keeps its eyes on what's most important. For the company, it's manufacturing high quality generic prescription medicines that pharmacists can dispense and patients can take with confidence. But the company doesn't stop there. Its pharmacy customers say what's most important to them is having product available and being a reliable supplier. To meet these demands, Ascend has taken a number of proactive steps such as quali- fying multiple APIs on products and get- ting multiple sites approved for the man- ufacture of high velocity molecules. It also looks to complete real time three year stability studies so it can offer three years of product expiration dating on key items. This allows Ascend to keep higher inventory levels on hand without the fear of product going short dated. This way it can meet the immediate needs of new inquiries in many cases. With two U.S.A. acquisitions now complete, Ascend brings API and fin- ished dose manufacturing into its book of capabilities here. These new facilities complement its two U.S. approved facil- ities in India, both of which are undergoing expansion and a third which is under con- struction. Combined, all these resources drive its very robust pipeline, which consists of more than 50 molecules awaiting FDA approval and more than 100 more under development. It's through investments like these that Ascend will be positioned to be a top-tier supplier now and in the years to come. But still, Ascend does not stop there. With a commitment to both customer and patient satisfaction, Ascend employs a physician Chief Medical Officer who is available 24/7 to answer questions from pharmacists, physicians and even patients directly. Its CMO is a practicing primary care physician who responds prompt- ly to all calls regarding questions on health issues with any Ascend product. Many of the company's customers have met its CMO at various trade events, and he assists hundreds of patients each year, providing needed medical direction or just peace of mind. It's clear to see that Ascend's focus is unobstructed in its aim to bring quality to its pharmacy customers and patients. Ascend has worked hard to gain your trust, and will work harder yet to retain it. Visit Ascend Laboratories at booth #232. NYMOX PROVIDES UPDATE ON FEXAPOTIDE DEVELOPMENT Nymox Pharmaceutical Corporation has provided an update on the company's devel- opment activities for Fexapotide Triflutate, its new drug for prostate enlargement. The company is very pleased with the progress it has made, which is in line with its previous timeline announcements. The company now expects to submit its initial filing seek- ing approval for Fexapotide Triflutate in the next few weeks. Nymox intends to provide fuller details at the above time. For more information, email info@nymox.com or call 800.936.9669. FDA LIFTS PARTIAL CLINICAL HOLD ON KARYOPHARM'S SELINEXOR CLINICAL TRIALS Karyopharm Therapeutics Inc., a clini- cal-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) Division of Hematology Products has lifted the par- tial clinical hold placed on the clinical tri- als for selinexor (KPT-330), enabling patient enrollment and dosing of new patients in the company's clinical trials of selinexor in hematological malignancies. The partial clinical hold was not the result of any patient death or any change in the safety profile of selinexor. Enrollment may now resume in all selinexor studies in hematologic malig- nancies, including the STORM study in refractory multiple myeloma, the SADAL study in relapsed/refractory dif- fuse large B-cell lymphoma (DLBCL), and the STOMP study of selinexor and backbone therapies in multiple myeloma. In addition, Investigator Sponsored Trials in hematologic malignancies with selinexor may resume accruing patients. Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, stated, "The Karyopharm team worked diligently to update and submit the required documents to the FDA, which allowed the hematology divison to expedi- tiously remove the partial clinical hold. We anticipate that the solid tumor divisions will follow suit shortly. Patient enrollment is again underway in our hematologic oncology studies. Our previously disclosed enrollment rates and timelines for both ongoing and planned trials are not expect- ed to be materially impacted." About Selinexor Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor sup- pressor proteins in the cell nucleus. This reinitiates and amplifies their tumor sup- pressor function and is believed to lead to the selective induction of apoptosis in can- cer cells, while largely sparing normal cells. To date, more than 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multi- ple cancer indications, including in multi- ple myeloma in combination with low- dose dexamethasone (STORM) and back- bone therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal ran- domized Phase 3 study of selinexor in combination with bortezomib (Velcade ® ) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to fur- ther inform the company's clinical devel- opment priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. is a clini- cal-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treat- ment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addi- tion to single-agent and combination activ- ity against a variety of human cancers, SINE compounds have also shown biolog- ical activity in models of neurodegenera- tion, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development. For more information, visit www.karyopharm.com.